Why Farbe Firma is the Top Manufacturer of Hyoscine Butylbromide Injection
- Maulik Sudani
- Jun 16
- 7 min read
Last Updated: June 16, 2026
TL;DR: Hyoscine Butylbromide Injection — a sterile, clear, colourless aqueous solution of hyoscine butylbromide (scopolamine butylbromide), a quaternary ammonium antimuscarinic antispasmodic, supplied commonly as a 20 mg/1 mL ampoule for intramuscular or intravenous use — is a frontline hospital agent for the rapid relief of acute smooth-muscle spasm of the gastrointestinal, biliary and genitourinary tracts, including the colic of renal and biliary stones, and for reducing spasm and secretions during endoscopy, radiology and end-of-life care. Because the dose is given parenterally and reliable relief of painful spasm depends on an accurate, reproducible dose, each ampoule must deliver an exact, sterile, particulate-free amount at the labelled concentration, with the assay, the impurity and degradation profile, solution pH, fill volume, low particulate and endotoxin, a validated sterilisation route and verified container-closure integrity all mattering to safety and shelf life. Farbe Firma Pvt Ltd manufactures WHO-GMP certified Hyoscine Butylbromide Injection at our Gujarat, India facility and supplies it to hospital pharmacy, emergency, surgical, endoscopy and palliative-care services, tenders, distributors and brand owners across 30+ countries.
Key Takeaways
Drug class: Quaternary ammonium antimuscarinic (anticholinergic) antispasmodic — Hyoscine Butylbromide Injection is given intramuscularly or intravenously for the rapid relief of acute spasm of the gastrointestinal, biliary and genitourinary smooth muscle, including renal and biliary colic, and for spasm and secretion control during endoscopy, radiology and palliative care.
Certified manufacturing: WHO-GMP certified plant, ISO Class 5 aseptic core, validated water-for-injection loops, dedicated solution compounding and ampoule filling lines, control of the stability-indicating assay, the impurity profile, solution pH, fill volume, particulate and endotoxin for a small-volume parenteral, with container-closure integrity verification on every batch.
CTD-ACTD dossier support: Full eCTD and ACTD modules, ICH Q1A long-term and accelerated stability data, ICH Q1B photostability data, sterilisation and container-closure data, drug master files and CEP-style documentation for registrations including ministry-of-health, hospital-formulary and institutional tenders.
End-to-end CDMO services: Sterile-solution contract manufacturing, third-party manufacturing, private-label artwork, multilingual leaflets, tamper-evident tender-ready ampoule packaging and import/export coordination for buyers in Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
Introduction: Why Hyoscine Butylbromide Injection Demands a Premium Manufacturer
Hyoscine Butylbromide Injection holds a dependable, everyday place in emergency medicine, surgery, gastroenterology, radiology and palliative care across every market. It is the parenteral antispasmodic that clinicians reach for when acute, painful spasm of smooth muscle must be relaxed quickly — the cramping of irritable or obstructed bowel, the severe colic of a renal or biliary stone, the spasm that interferes with endoscopy or contrast radiology, and the distressing secretions and visceral spasm of end-of-life care. As a quaternary ammonium antimuscarinic, hyoscine butylbromide blocks muscarinic receptors on visceral smooth muscle and secretory glands, relaxing the spasm and drying secretions, while its quaternary structure limits its passage into the central nervous system. In each of these settings the dose delivered from each ampoule must be exact, sterile, particulate-free and reliably the same from unit to unit, because dependable, rapid relief of spasm depends on a precise, reproducible dose delivered in a small volume.
That clinical reality places real demands on the manufacturer. The product is presented as a low-volume aqueous solution that must stay a clear, colourless solution within a defined pH window throughout shelf life and must remain compatible with the common diluents into which it may be mixed for slow intravenous use. The assay of hyoscine butylbromide must be exact; the impurity and degradation profile — including control of any hydrolysis products of the ester — must stay within tight limits; the pH and the deliverable volume must be controlled tightly so each ampoule gives the labelled dose at the labelled concentration; the solution must be free of visible and sub-visible particulates and low in endotoxin; and it must be sealed in an ampoule whose container-closure integrity holds across shelf life. Choosing a Hyoscine Butylbromide Injection manufacturer that treats the stability-indicating assay, pH and fill-volume control, the validated sterilisation route, particulate and endotoxin control and container-closure integrity as core engineering disciplines is what protects the patient at the point of care.
What Sets a World-Class Hyoscine Butylbromide Injection Manufacturer Apart
A world-class manufacturer of Hyoscine Butylbromide Injection invests in three areas that weaker suppliers underfund: a precise, stability-indicating assay of hyoscine butylbromide with the tight related-substance and degradation-product control by HPLC that an antimuscarinic ester parenteral demands, a robust, validated sterilisation strategy — terminal moist-heat sterilisation where the formulation and ampoule permit it, otherwise sterile filtration and aseptic filling — that protects the assay, the pH and the clarity of the solution, and tender-ready dossier support for a high-volume hospital-formulary product procured through pharmacy and ministry-of-health channels. It starts with the active — pharmacopoeial-grade hyoscine butylbromide sourced from qualified, audited API makers, with full assay, related-substance and impurity profiling and certificates of analysis verified by the receiving laboratory before the material enters production.
Compounding and filling then have to defend both the assay and the dose. The bulk solution is compounded in water-for-injection at the slightly acidic pH that keeps the hyoscine butylbromide ester stable and resists hydrolysis, sterile-filtered through 0.22 µm membrane, and filled into ampoules under ISO Class 5 conditions, with the validated sterilisation route — terminal moist-heat where qualified, otherwise full aseptic processing — locked in the master batch record. Filled ampoules are 100 % inspected for fill, seal, clarity and particulate defects; in-process and release testing confirm the assay of hyoscine butylbromide by validated HPLC, the related-substance profile, solution pH, deliverable volume, visible and sub-visible particulate matter, and endotoxin is held well within limits so the solution is safe for intramuscular and intravenous administration. Because the ester is susceptible to hydrolysis, pH control and the sterilisation thermal load are validated together so terminal heat does not push degradation products over specification.
Quality Systems Behind Every Hyoscine Butylbromide Injection
Every Farbe Firma Hyoscine Butylbromide Injection batch is released only after a full stack of quality checks: stability-indicating HPLC assay of hyoscine butylbromide against pharmacopoeial reference standards, control of related substances and degradation products by HPLC, solution pH, deliverable (fill) volume, clarity and colour of the solution, visible and sub-visible particulate matter, bacterial endotoxin by LAL, sterility by membrane filtration, and container-closure integrity for the ampoule format. Certificates of analysis are issued with full traceability back to each API lot, the primary-packaging lot and the qualified person responsible for release.
Around those release tests sits a deeper quality architecture: validated water-for-injection generation and looped distribution, qualified HVAC with continuous environmental monitoring, validated sterilisation and depyrogenation equipment, validated ampoule-filling lines with 100 % inspection, and an electronic batch record system tied into our deviation, change-control and CAPA workflows. Because hyoscine butylbromide is given to relieve acute, painful spasm and the assay, pH, clarity and particulate burden of the solution drive both efficacy and safety, we treat the stability-indicating HPLC assay, the solution pH, the deliverable volume and the related-substance profile as critical quality attributes and trend them across batches, not merely as one-off release tests. Stability is tracked under both long-term (25 °C / 60 % RH) and accelerated (40 °C / 75 % RH) ICH Q1A conditions, with ICH Q1B photostability challenge, and in-use dilution stability is established where slow intravenous dilution is supported.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Hyoscine Butylbromide Injection manufacturer for Global Buyers
Farbe Firma Pvt Ltd manufactures more than 100 sterile injectables, including a broad small-volume parenteral portfolio across emergency, surgical, gastrointestinal, anaesthesia and supportive-care categories. For Hyoscine Butylbromide Injection specifically, we supply the 20 mg/1 mL single-dose ampoule of sterile solution under WHO-GMP conditions, with country-specific strengths, fill configurations, tamper-evident packs and pack counts available under contract manufacturing agreements. Every batch is released to WHO-GMP standards, with the underlying CTD or ACTD dossier — including the stability-indicating-assay, pH, sterilisation and container-closure data package — ready to hand for registration and tender qualification.
Our CDMO services scale cleanly from single-hospital supply to full national tender procurement. We prepare complete eCTD and ACTD modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets, and coordinate shipping and logistics to the destination market. When a buyer needs Hyoscine Butylbromide Injection at tender scale our regulatory, manufacturing and logistics teams move as one: dossier, validation reports, artwork, line slot and shipment plan delivered as a single coordinated package.
Buyers stay with Farbe Firma because of audit-readiness and communication. Customer auditors are welcomed onto the plant floor and into the compounding and filling suites; our quality unit answers technical queries with primary data, not slogans; and our reviewer team — practising pharmacists and R&D scientists — can talk through API sourcing, stability-indicating assay development, related-substance and ester-hydrolysis control, pH and buffer design, the choice between terminal sterilisation and aseptic filling, fill-volume and deliverable-dose control, dilution-compatibility and in-use stability, particulate and endotoxin control, container-closure integrity and shelf-life choices in real detail. For a high-volume parenteral antispasmodic where assay accuracy, pH and particulate control directly govern both efficacy and safety, that openness is exactly what global buyers tell us they value most.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified Hyoscine Butylbromide Injection manufacturer?
Yes. Farbe Firma Pvt Ltd holds WHO-GMP certification and manufactures Hyoscine Butylbromide Injection at a Gujarat, India facility with ISO Class 5 aseptic processing, dedicated solution compounding and ampoule filling lines, validated sterilisation, qualified water-for-injection systems, 100 % inspection and continuous environmental monitoring.
Which strengths and pack sizes of Hyoscine Butylbromide Injection do you supply?
Our standard presentation is the 20 mg/1 mL single-dose ampoule of sterile hyoscine butylbromide solution, for intramuscular or intravenous use. Custom strengths, fill configurations, ampoule formats, tamper-evident counts per pack and country-specific artwork are available under contract manufacturing agreements.
What is Hyoscine Butylbromide Injection mainly used for?
Hyoscine Butylbromide Injection is used for the rapid relief of acute smooth-muscle spasm of the gastrointestinal, biliary and genitourinary tracts — including renal and biliary colic — and to reduce spasm and secretions during endoscopy, radiology and palliative care. It is a quaternary ammonium antimuscarinic antispasmodic; Farbe Firma verifies the assay, clarity, deliverable volume, pH and particulate matter at release so each ampoule delivers a precise, reproducible dose.
Can Farbe Firma support country-specific registrations for Hyoscine Butylbromide Injection?
Yes. We provide full CTD and ACTD dossier modules, drug master files, ICH Q1A stability and ICH Q1B photostability packages, assay and related-substances method-validation data, sterilisation and container-closure reports, and translated package inserts and artwork for Spanish, French, Portuguese, Russian and Arabic markets. We support registrations and tender qualification in 30+ countries across Africa, LATAM, CIS, GCC, MENA and Southeast Asia.
What is the minimum order quantity for Hyoscine Butylbromide Injection contract manufacturing?
MOQs vary by strength, ampoule size, sterilisation route, label complexity and dossier requirements. For our small-volume parenteral presentations we accommodate hospital-scale and full national-tender-scale orders. Contact director@farbefirma.org for a specific quotation.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments